Back to Search
Start Over
223 Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience.
- Source :
-
Tumori [Tumori] 2018 Mar-Apr; Vol. 104 (2), pp. 128-136. Date of Electronic Publication: 2018 Apr 18. - Publication Year :
- 2018
-
Abstract
- Background: Radium-223 ( <superscript>223</superscript> Ra) chloride, an alpha emitter, has been shown to improve overall survival (OS) and pain control, and to delay skeletal-related events, in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Our retrospective observational study presents the first Italian experience on the efficacy and safety of <superscript>223</superscript> Ra therapy in routine clinical practice.<br />Methods: A total of 83 patients with metastatic CRPC were treated with <superscript>223</superscript> Ra at 3 Italian centers between August 2013 and August 2016. <superscript>223</superscript> Ra-chloride (55 kBq/kg) was administered every 4 weeks for a total of 6 cycles. Primary endpoints were OS and progression-free survival (PFS). Secondary endpoints included toxicity, pain evaluation using numeric rating scale (NRS), symptomatic skeletal-related events and biomarkers response.<br />Results: Patients had a median age of 75 (range 53-89) years. The majority of men showed a Gleason score of 7, 8, or 9. Forty-one patients completed 6 treatment cycles; 33 stopped treatment before completing 6 cycles. Nine were still receiving therapy at the time of data collection. At the end of therapy, NRS pain scores significantly improved ( p < .000001). OS was a mean of 10.1 months, while median OS had not been attained. According to Kaplan-Meier estimation, OS and PFS were 17.5 and 7.7 months, respectively. There was a significant correlation between OS and PFS with the number of <superscript>223</superscript> Ra cycles; patients receiving all 6 cycles experienced the major benefit from the therapy. <superscript>223</superscript> Ra was well-tolerated.<br />Conclusions: <superscript>223</superscript> Ra alpha therapy is an important therapeutic option for men with CRPC and symptomatic skeletal metastases.
- Subjects :
- Aged
Aged, 80 and over
Biomarkers, Tumor metabolism
Bone Neoplasms secondary
Disease-Free Survival
Humans
Italy
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Grading
Retrospective Studies
Bone Neoplasms drug therapy
Bone Neoplasms radiotherapy
Chlorides therapeutic use
Prostatic Neoplasms, Castration-Resistant drug therapy
Prostatic Neoplasms, Castration-Resistant radiotherapy
Radium therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2038-2529
- Volume :
- 104
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Tumori
- Publication Type :
- Academic Journal
- Accession number :
- 29714668
- Full Text :
- https://doi.org/10.1177/0300891618765571